Urinary ctDNA assay studied for detecting minimal residual disease in high-risk NMIBC

Prospective · UroToday · 2026-10-05. Number 5 in the UrologyWatch Top 5 for October 6, 2026.

A study evaluates whether a urinary circulating tumor DNA assay can detect minimal residual disease in patients with high-risk non-muscle invasive bladder cancer. Design details such as prospective or retrospective enrollment are not specified in the available source.

Why it matters: Non-invasive molecular monitoring could eventually complement cystoscopy for surveillance in high-risk NMIBC, pending further validation of study design and results.

Source: UroToday

The full October 6, 2026 edition · Today's urology news